LHLeanne Carijn Helgers

Leanne Carijn Helgers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leanne Carijn Helgers has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Teunis B. H. Geijtenbeek

    Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands

    6 shared publications
  • John L. van Hamme

    Amsterdam institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

    2 shared publications
  • Adithya Sridhar

    OrganoVIR Labs, Emma Children’s Hospital, Department of Pediatric Infectious Diseases, Amsterdam UMC, Academic Medical Center, Amsterdam Institute for Infection and Immunity, Amsterdam Institute for Reproduction and Development, University of Amsterdam

    1 shared publication
  • Alisha D. Biharie

    Department of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands

    1 shared publication
  • Anoop T. Ambikan

    The Systems Virology Lab, Division of Clinical Microbiology, Department of Laboratory Medicine, ANA Futura, Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • Balthasar A. Heesters

    Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Rabies virus infection and immune activation in human epidermal keratinocytes: Implications for rabies transmission

    by Keshia Kroh, Alisha D. Biharie, Eleanor M. Marshall, Redwan Rahmat, Debby Schipper, Leanne C. Helgers, Teunis B.H. Geijtenbeek, Corine H. GeurtsvanKessel, Carmen W.E. Embregts


  • Open Access

    Microglia cause HIV-induced transcriptional and metabolic changes in human neural organoids

    by Pamela E. Capendale, Leanne C. Helgers, Anoop T. Ambikan, Renata Vieira de Sá, Katja C. Wolthers, Teunis B. H. Geijtenbeek, Adithya Sridhar, Ujjwal Neogi, Dasja Pajkrt

    Human immunodeficiency virus (HIV) can invade the central nervous system during the initial stages of infection and contribute to HIV-associated neurocognitive disorder, affecting up to 50% of people living with HIV (PLWH). To investigate HIV-1–induced immunometabolic changes in the brain, we used a three-dimensional microglia-embedded human neural organoid model. Transcriptomic analysis and genome-scale metabolic modeling revealed that HIV-1 infection led to more pronounced transcriptional changes in the presence of microglia, including upregulation of pro-inflammatory pathways. We identified CCR6, important for HIV-1 permissiveness, to be significantly upregulated upon infection. Metabolic analysis showed increased expression in metabolite transport-related genes, including solute carrier (SLC) genes and altered amino acid metabolism, particularly involving arginine, proline, and tyrosine. These microglia-driven immunometabolic changes may contribute to neuronal dysregulation and, subsequently, neurological complications, which are often observed in PLWH. Early detection of these alterations could support timely therapeutic intervention to improve HIV-related neurologic insult.


  • Open Access

    Heparin Provides Antiviral Activity Against Rhinovirus-16 via an Heparan Sulfate Proteoglycan-Independent Mechanism

    by Leanne C. Helgers, Killian E. Vlaming, Tanja M. Kaptein, Julia Eder, Jan Willem Duitman, Teunis B. H. Geijtenbeek

    Human rhinovirus 16 (HRV-16) is a major cause of common colds and can exacerbate asthma and COPD, yet no approved antiviral treatments exist. Heparin, a highly sulfated polysaccharide, is known to block viral infection of many viruses that require attachment to heparan sulfate proteoglycans (HSPGs). Here, we investigated whether heparin inhibits HRV-16 infection. HRV-16 uses ICAM-1 as its attachment receptor and lacks a confirmed HSPG-binding mechanism. Notably, heparin inhibited HRV-16 infection in vitro in a dose- and time-dependent manner. Pre-treatment of either cells or virus particles with unfractionated heparin significantly reduced HRV-16 RNA expression at 24 and 48 h post-infection. In contrast, low-molecular-weight heparins blocked infection of HRV-16 significantly less effectively compared to unfractionated heparins. Our findings suggest that the inhibitory effect of unfractionated heparin on HRV-16 infection is likely independent of specific HSPGs interactions and may be mediated by the size and highly negative charge of unfractionated heparin. Importantly, the ability of unfractionated heparin to block viruses that do not require HSPGs for attachment implies a broader antiviral potential as a prophylactic or therapeutic agent against a variety of respiratory viruses.


  • Open Access

    Human CD127 negative ILC2s show immunological memory

    by Laura Mathä, Lisette Krabbendam, Sergio Martinez Høyer, Balthasar A. Heesters, Korneliusz Golebski, Chantal Kradolfer, Maryam Ghaedi, Junjie Ma, Ralph Stadhouders, Claus Bachert, et al.

    ILC2s are key players in type 2 immunity and contribute to maintaining homeostasis. ILC2s are also implicated in the development of type 2 inflammation–mediated chronic disorders like asthma. While memory ILC2s have been identified in mouse, it is unknown whether human ILC2s can acquire immunological memory. Here, we demonstrate the persistence of CD45RO, a marker previously linked to inflammatory ILC2s, in resting ILC2s that have undergone prior activation. A high proportion of these cells concurrently reduce the expression of the canonical ILC marker CD127 in a tissue-specific manner. Upon isolation and in vitro stimulation of CD127−CD45RO+ ILC2s, we observed an augmented ability to proliferate and produce cytokines. CD127−CD45RO+ ILC2s are found in both healthy and inflamed tissues and display a gene signature of cell activation. Similarly, mouse memory ILC2s show reduced expression of CD127. Our findings suggest that human ILC2s can acquire innate immune memory and warrant a revision of the current strategies to identify human ILC2s.


  • Open Access

    Dengue Virus Infects Human Skin Langerhans Cells through Langerin for Dissemination to Dendritic Cells

    by Leanne C. Helgers, Nadia C.H. Keijzer, John L. van Hamme, Joris K. Sprokholt, Teunis B.H. Geijtenbeek


  • Open Access

    Vaginal bacterium Prevotella timonensis turns protective Langerhans cells into HIV‐1 reservoirs for virus dissemination

    by Nienke H van Teijlingen, Leanne C Helgers, Ramin Sarrami‐Forooshani, Esther M Zijlstra‐Willems, John L van Hamme, Celia Segui‐Perez, Marleen Y van Smoorenburg, Hanneke Borgdorff, Janneke Hhm van de Wijgert, Elisabeth van Leeuwen, et al.

    Dysbiosis of vaginal microbiota is associated with increased HIV‐1 acquisition, but the underlying cellular mechanisms remain unclear. Vaginal Langerhans cells (LCs) protect against mucosal HIV‐1 infection via autophagy‐mediated degradation of HIV‐1. As LCs are in continuous contact with bacterial members of the vaginal microbiome, we investigated the impact of commensal and dysbiosis‐associated vaginal (an)aerobic bacterial species on the antiviral function of LCs. Most of the tested bacteria did not affect the HIV‐1 restrictive function of LCs. However, Prevotella timonensis induced a vast uptake of HIV‐1 by vaginal LCs. Internalized virus remained infectious for days and uptake was unaffected by antiretroviral drugs. P. timonensis‐exposed LCs efficiently transmitted HIV‐1 to target cells both in vitro and ex vivo. Additionally, P. timonensis exposure enhanced uptake and transmission of the HIV‐1 variants that establish infection after sexual transmission, the so‐called Transmitted Founder variants. Our findings, therefore, suggest that P. timonensis might set the stage for enhanced HIV‐1 susceptibility during vaginal dysbiosis and advocate targeted treatment of P. timonensis during bacterial vaginosis to limit HIV‐1 infection.